Drug intelligence / Profile preview

AC-2010

Development stage: Preclinical
Modality: Small Molecules

Overview

AC-2010 is a lipid droplet binding thalidomide analog. As a thalidomide analog, it is expected to function as a cereblon E3 ligase modulator, a mechanism shared by other immunomodulatory drugs (IMiDs). The drug has been shown to activate endoplasmic reticulum (ER) stress and suppress hepatocellular carcinoma (HCC) in a chemically induced transgenic mouse model. Its interaction with lipid droplets leads to calcium release from the ER, inducing ER stress and ultimately apoptosis in cancer cells.

Beyond the preview

Go deeper on AC-2010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-2010.